Of the 15 patients who received first-line alectinib and for whom information was available, the median time from diagnosis of metastatic ALK-positive NSCLC to lorlatinib initiation was 13.4 months (95% CI: 8.8–16.7), while the median duration of therapy on alectinib was 12.0 months (95% CI: 7.0–15.0). Here, ALK is linked to non-small cell lung carcinoma.